• AnteBC – Breast Cancer Polygenic Risk Score Test

    Breast cancer is the most common cancer in women. AnteBC estimates a woman's genetic risk of developing breast cancer using a polygenic risk score. The AnteBC test provides risk-based personalized recommendations and follow-up actions to prevent or detect breast cancer at an early stage when it is still treatable. AnteBC test is recommended for women between the ages of 30 and 75 of primarily European ancestry.

    Read more
  • AntePC – Prostate Cancer Polygenic Risk Score Test

    Prostate cancer is the most common malignancy in men that can be aggressive causing premature mortality. AntePC test estimates man’s genetic risk of developing prostate cancer using a polygenic risk score. The AntePC test provides risk-based personalized recommendations and follow-up actions to prevent or detect prostate cancer at an early stage when it is still treatable. AntePC test is recommended for men between the ages of 40 and 70 of primarily European ancestry.

    Read more
  • AnteCRC – Colorectal Cancer Polygenic Risk Score Test

    Colorectal cancer is a common malignancy of the digestive system with a poor prognosis and high morbidity and mortality rate. AnteCRC estimates a genetic risk of developing colorectal cancer using a polygenic risk score. AnteCRC test provides risk-based personalized recommendations and follow-up actions to prevent or detect colorectal cancer at an early stage when it is still treatable. AnteCRC test is recommended for men and women between the ages of 40 and 75 of primarily European ancestry.

    Read more
  • AnteMEL – Skin Melanoma Polygenic Risk Score Test

    Melanoma is the most aggressive form of skin cancer. AnteMEL test estimates the genetic risk of developing melanoma using a polygenic risk score. AnteMEL test gives risk-based recommendations for melanoma risk management and screening. AnteMEL test is recommended for men and women between the ages of 18 and 70 of primarily European ancestry.

    Read more